A Personalized Cancer Vaccine that Induces Synergistic Innate and Adaptive Immune Responses

Area of Science:

• Immunology
• Oncology
• Nanotechnology

Background:

• Effective cancer vaccines require activation of both innate and adaptive immune cells.
• Personalized cancer vaccines face challenges due to cancer cell heterogeneity and the need for neoantigen identification.
• Current therapeutic strategies for acute myeloid leukemia (AML) have limitations.

Purpose of the Study:

• To present extracellular nanovesicles derived from alpha-galactosylceramide-conjugated autologous AML cells (ECNV-αGC) as a personalized therapeutic vaccine.
• To demonstrate that ECNV-αGC activates both innate and adaptive immune responses without neoantigen identification.
• To evaluate the efficacy of ECNV-αGC in reducing AML burden and improving survival in mice.

Main Methods:

• Development of ECNV-αGC from autologous AML cells conjugated with alpha-galactosylceramide.
• In vivo studies in mice with AML to assess immune cell activation (iNKT cells and CD8+ T cells) and anti-leukemic effects.
• Evaluation of ECNV-αGC's antigen-presenting capabilities and activation of iNKT cells in human samples.

Main Results:

• ECNV-αGC vaccination activated both invariant natural killer T (iNKT) cells and leukemia-specific CD8+ T cells in mice with AML, promoting long-term immune memory.
• ECNV-αGC acted as an antigen-presenting platform, directly activating antigen-specific CD8+ T cells independently of dendritic cells.
• Vaccination with ECNV-αGC significantly reduced AML burden and increased leukemia-free survival in cytarabine-treated mice.
• Human AML-derived ECNV-αGCs activated iNKT cells in healthy individuals and AML patients, irrespective of prior treatment response.

Conclusions:

• Autologous AML-derived ECNV-αGCs represent a promising personalized therapeutic vaccine strategy for AML.
• This approach efficiently establishes AML-specific long-term immunity by activating innate and adaptive immune responses.
• ECNV-αGC bypasses the need for neoantigen identification, simplifying personalized cancer vaccine development.